Australia's most trusted
source of pharma news
Saturday, 21 June 2025
Posted 17 June 2025 AM
Johnson & Johnson Innovative Medicine has suffered a stunning loss in its legal battle against Samsung Bioepis over the latter's Stelara biosimilar.
Last year J&J subsidiary Janssen sued Samsung Bioepis, in a case that became based on three child 'innovation' patents that had an expiry date of 24 September 2027. They were derived from a parent patent that is still under consideration, due to expire on 24 September 2039 if granted.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.